EZH2 and breast cancer: Similarly, another study illustrated that methylation of EZH2 by PRMT1 at R342 promoted breast cancer cell EMT, invasion, and metastasis, and high levels of EZH2 methylation was associated with poor clinical outcome in breast cancer patients [28].